Guardant Health has joined forces with Adicon, a leading clinical laboratory company in China, to bring its advanced cancer profiling solutions to biopharmaceutical companies conducting clinical trials in the region. This collaboration promises to revolutionise patient selection and cancer research by leveraging cutting-edge liquid biopsy and genomic profiling technologies.
Guardant Health will provide Adicon with access to its state-of-the-art diagnostic tools, including the Guardant360 and GuardantOmni liquid biopsy tests, and the Guardant360 TissueNext for tissue-based analysis. These technologies enable researchers to efficiently identify patients with the appropriate molecular profiles for their clinical trials, enhancing the precision of patient screening and streamlining trial enrolment. Additionally, the Guardant Reveal test, designed for monitoring residual disease and cancer recurrence, will now be available to support early-stage cancer research and development efforts in China. This strategic move underscores Guardant Health’s commitment to accelerating progress in the fight against cancer.
The partnership is a milestone moment for both organisations. Helmy Eltoukhy, co-CEO of Guardant Health, emphasised the significance of this collaboration, citing Adicon’s robust expertise in clinical laboratory services as a critical asset in delivering these advanced diagnostics to biopharmaceutical companies in China. By uniting Guardant Health’s transformative technology with Adicon’s local infrastructure, the partnership aims to empower researchers to develop next-generation cancer therapies that address the region’s growing oncology challenges.
With rising cancer incidence rates in China driving an increased focus on clinical trials, Adicon’s capabilities are set to expand significantly through this partnership. Adicon’s CAP-accredited laboratory in Shanghai will serve as the hub for this effort, enabling the company to support a rapidly evolving biopharmaceutical landscape. Ling Yang, Adicon’s chairwoman, and Lawrence Wang, CFO, expressed optimism about the collaboration’s potential to enhance cancer research and provide life-changing solutions for patients.
Guardant Health is a leader in precision oncology, leveraging advanced technology to transform cancer diagnostics and improve patient outcomes worldwide.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
